GlassScriptPhysician profile
Peter Kent Boothman
NPI 1588018170
$1,668.21
in general payments reported to CMS, 2019-2025
15 companies · $453 in 2025
The $453 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $223 · 2021: $158 · 2022: $59.36 · 2023: $165 · 2024: $348 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.24 |
| Education | $168.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $458.47 | 2023-2025 | |
| Janssen Biotech, INC. | $267.98 | 2020-2025 | Tremfya |
| Allergan, INC. | $239.51 | 2019-2021 | |
| Lilly USA, LLC | $124.08 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $121.86 | 2019 | |
| Ucb, INC. | $93.34 | 2024-2025 | Bimzelx |
| Sun Pharmaceutical Industries INC. | $84.46 | 2024-2025 | |
| Amgen INC. | $55.88 | 2022-2024 | Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $43.46 | 2019 | |
| Galderma Laboratories, L.P. | $42.55 | 2025 | Nemluvio |
| Leo Pharma INC. | $33.18 | 2024-2025 | Adbry, Anzupgo |
| Krystal Biotech INC | $33.17 | 2024 | Vyjuvek |
| Dermavant Sciences, INC. | $30.56 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $23.99 | 2022 | |
| Biofrontera INC. | $15.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Boothman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.